3-氯-2-氟-5-(三氟甲基)苄基溴 | 261763-09-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-2-氟-5-(三氟甲基)苄基溴
• 英文名称: 1-(bromomethyl)-3-chloro-2-fluoro-5-(trifluoromethyl)benzene
• 英文别名: 3-Chloro-2-fluoro-5-(trifluoromethyl)benzyl bromide
• CAS: 261763-09-1
• 化学式: C₈H₄BrClF₄
• 分子量: 291.47
• InChiKey: SPNVJHWULHTZHG-UHFFFAOYSA-N

物化性质

• 沸点：
  213.1±35.0 °C(Predicted)
• 密度：
  1.728±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  8

反应信息

• 作为反应物：
  描述：

  7-(4,4,4-trifluoro-1,1-dimethyl-3-oxobutyl)-2,3-dihydrobenzofuran-5-carbonitrile 、 3-氯-2-氟-5-(三氟甲基)苄基溴 生成 7-[3-(3-chloro-2-fluoro-5-trifluoromethylbenzyl)-4,4,4-trifluoro-3-hydroxy-1,1-dimethylbutyl]-2,3-dihydrobenzofuran-5-carbonitrile
  参考文献：
  名称：

  Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

  摘要：

  化合物的公式（IA）和公式（IB）1，其中R1、R2、R3、R4、R5和R6如公式（IA）或公式（IB）所定义，或其互变异构体、前药、溶剂化物或盐；包含这些化合物的药物组合物；以及使用这些化合物调节糖皮质激素受体功能、治疗由糖皮质激素受体功能介导或以炎症、过敏或增生过程为特征的疾病状态或情况的方法。

  公开号：

  US20040029932A1

文献信息

• INHIBITORS OF STEAROYL-COA DESATURASE
  申请人：Gillespie Paul

  公开号：US20090149466A1

  公开（公告）日：2009-06-11

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

  提供以下式(I)化合物： 以及药用可接受的盐，其中取代基如说明书中所披露。这些化合物以及包含它们的药物组合物可用于治疗诸如肥胖等疾病。
• [EN] ANTIDIABETIC SPIROCHROMAN COMPOUNDS<br/>[FR] COMPOSÉS DE SPIROCHROMANE ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2018118670A1

  公开（公告）日：2018-06-28

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面有用。本发明的化合物可能在治疗2型糖尿病以及与该疾病常相关的病症，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症方面有用。
• [EN] GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] MIMETIQUES DU GLUCOCORTICOIDE, PROCEDES DE FABRICATION DE CES MIMETIQUES, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2003082787A1

  公开（公告）日：2003-10-09

  Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate,or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  式（IA）和式（IB）的化合物，其中R1、R2、R3、R4、R5和R6如本说明所定义的适用于式（IA）或式（IB），或其互变异构体、前药、溶剂化合物或盐；含有这些化合物的药物组合物，以及利用这些化合物调节糖皮质激素受体功能的方法、治疗由糖皮质激素受体功能介导的疾病状态或病情特征或患者体内的炎症、过敏或增殖过程的方法。
• PYRROLIDINEANILINES
  申请人：Frazee James S.

  公开号：US20100216813A1

  公开（公告）日：2010-08-26

  The present invention relates to a compound represented by the following formula I or a pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , and y are defined herein. The present invention further relates to compositions that include the compound of the present invention as well as a method of treating a patient from endometreosis or uterine fibroids.

  本发明涉及以下式I或其药学上可接受的盐所代表的化合物；其中R1，R2和y在此定义。本发明还涉及包含本发明化合物的组合物以及治疗子宫内膜异位症或子宫肌瘤患者的方法。
• Antidiabetic spirochroman compounds
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10968232B2

  公开（公告）日：2021-04-06

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新型化合物及其药学上可接受的盐类是G-蛋白偶联受体40（GPR40）的激动剂，可用于治疗、预防和抑制由G-蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗 2 型糖尿病以及通常与这种疾病相关的病症，包括肥胖和脂质紊乱，如混合性或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症。